Commercialisation. A party may only Commercialise or disseminate the Project IP with the prior written consent of the other parties. Any Commercialisation of Project IP will be subject to a separate commercialisation agreement as agreed between the parties. Privacy & Data Personal Information The Participant must: comply with the Privacy Xxx 0000 (Cth) and all other applicable privacy laws as may be in force from time to time which regulate the collection, storage, use and disclosure of information, including the Australian Privacy Principles; not disclose any Personal Information under or in connection with this Agreement to any entities located outside of Australia without MLA's prior written consent; and ensure that all of its subcontractors or agents comply with this clause 19.1. Without limiting clause 19.1: where the Participant collects Personal Information for or on behalf of MLA, the Participant: must only use and disclose that information for the purpose for which it is collected; and must not publish, disseminate or Commercialise the Personal Information in any way; in relation to any Personal Information that the Participant provides to MLA under this Agreement, the Participant warrants that it has: before providing the Personal Information to MLA, notified all individuals to whom the Personal Information relates that it will be disclosing their Personal Information to MLA for the purposes of the Project and obtained any required consent to such disclosure; and provided the individuals with the location of where the privacy policy of MLA or ISC (as applicable) can be found, which is via Privacy Policy or ISC Privacy Policy respectively; in relation to any Personal Information provided to the Participant by MLA under this Agreement, the Participant must: only store, use, disclose or otherwise handle the information for the specific purposes for which it was provided to the Participant under this Agreement; and co-operate with any reasonable request or direction of MLA which relates to the protection of the information; and the Participant must promptly notify MLA of any complaint that it receives concerning the Personal Information under this Agreement.
Commercialisation. All business decisions, including but not limited to the selection of the trademark(s) for Product, pricing, reimbursement, package design, sales and promotional activities and the decision to launch or continue to market a Product in a particular country in the Territory, shall be within the sole discretion and responsibility of THERAVANCE. Notwithstanding the above it is agreed that THERAVANCE shall otherwise use reasonable efforts consistent with its normal business practices to market and promote Product. In doing so it will use the same level of effort as with its other, similar products of similar sales potential. Failure to use reasonable efforts as qualified herein can be considered a material breach in accordance with the provisions of Article 14.1.
Commercialisation. 51.1 The parties to this Agreement acknowledge that effective commercialisation of research and development outcomes are fundamental to CSIRO’s future. In order to facilitate staff involvement in commercialisation activities, affected officers will be provided with timely information about their rights, entitlements and the conditions that apply, so that they are able to make an informed decision about whether or not they wish to participate.
Commercialisation. 5.1 Subject to Clause 5.16, Almirall’s core obligation in relation to Commercialisation of Product shall be to use its Commercially Reasonable Efforts to achieve Launch of the Product for the first Indication within six (6) months after the grant of Marketing Authorisation (including pricing and/or reimbursement approval where such approval is necessary or industry practice for Launch) for Product for that Indication in each Major European Market and in the other countries in the Territory. Thereafter Almirall shall use its Commercially Reasonable Efforts in each Major European Market and in the other countries in the Territory to realise the market potential of Product for that Indication and any subsequent Indication for which GW Pharma obtains a Marketing Authorisation save as provided below:
Commercialisation. 7.1 Except for the activities to be conducted by Dermira under the Pre-Launch Medical Affiairs Plan as set forth in Section 9.3, Dermira shall have no right to undertake Dermira Commercial Activities for the Product in the Promotion Indication in any country within the Territory unless and until UCB has been granted Regulatory Approval to Commercialise the Product in the Development Indication, unless such Dermira Commercial Activities are identified in the Commercialisation Plan as to be conducted prior to such Regulatory Approval. Notwithstanding anything to the contrary in this Agreement, Dermira shall have no diligence obligations with respect to the Promotion Indication but shall have those rights with respect to the Promotion Indication as set forth in this Agreement.
Commercialisation. In cases of commercialisation where tendering will be part of the process, the members of the joint WFA-ASD committee shall make every reasonable effort to come to an agreement on the criteria related to human resources issues (e.g. terms and conditions of employment, pension and health care benefits, the take-up number of employees) to be used in the request for proposal (RFP) process. The committee will respect the contracting rules of the federal government.
Commercialisation. The obligations of each of the Parties in respect of commercialisation will be as contained in the relevant Commercialisation Licence or Complementary Agreement (if any).
Commercialisation. (a) The Licensee shall use commercially reasonable endeavours to develop a Complement Factor I therapy.
Commercialisation. 5.1 (a) Taking into account the complexity, and stage of development of the Licensed Products, Licensee shall use reasonable commercial efforts under the circumstances to research, develop and then commercialise Licensed Product in the United States, European Union and in other countries of the world in which Licensee can reasonably develop and market Licensed Product. The efforts of a Sub-Licensee and/or an Affiliate and/or a collaborator of Licensee shall be considered as efforts of Licensee.
Commercialisation. 5.1 Celldex shall use Diligent and Reasonable Efforts to develop and commercially exploit at least one Licensed Product in the Field and Territory.
